Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: A retrospective analysis

The Lancet Oncology

Volumn 13, Issue 8, 2012, Pages 802-809

  Senthi, Sashendra ^a   Lagerwaard, Frank J ^a   Haasbeek, Cornelis JA ^a   Slotman, Ben J ^a   Senan, Suresh ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ABLATION THERAPY; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOCAL METASTASIS; LUNG LESION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PRIORITY JOURNAL; RADIATION DOSE; REGIONAL METASTASIS; RETROSPECTIVE STUDY; STEREOTACTIC ABLATIVE RADIOTHERAPY; STEREOTACTIC BODY RADIATION THERAPY; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DOSE FRACTIONATION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NETHERLANDS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RADIOSURGERY; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84864342085     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70242-5     Document Type: Article

References (31)

1. Rami-Porta R, Ball D, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007, 2:593-602.
2. Rowell NP, Williams CJ Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable): a systematic review. Thorax 2001, 56:628-638.
3. Lagerwaard FJ, Senan S, van Meerbeeck JP, Graveland WJ Has 3-D conformal radiotherapy (3D CRT) improved the local tumour control for stage I non-small cell lung cancer?. Radiother Oncol 2002, 63:151-157.
4. Haasbeek CJ, Slotman BJ, Senan S Radiotherapy for lung cancer: clinical impact of recent technical advances. Lung Cancer 2009, 64:1-8.
5. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010, 303:1070-1076.
6. Baumann P, Nyman J, Hoyer M, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 2009, 27:3290-3296.
7. Grutters JP, Kessels AG, Pijls-Johannesma M, De Ruysscher D, Joore MA, Lambin P Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. Radiother Oncol 2010, 95:32-40.
8. Nagata Y, Hiraoka M, Mizowaki T, et al. Survey of stereotactic body radiation therapy in Japan by the Japan 3-D Conformal External Beam Radiotherapy Group. Int J Radiat Oncol Biol Phys 2009, 75:343-347.
9. Palma D, Visser O, Lagerwaard FJ, Belderbos J, Slotman BJ, Senan S Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol 2010, 28:5153-5159.
10. Pan H, Simpson DR, Mell LK, Mundt AJ, Lawson JD A survey of stereotactic body radiotherapy use in the United States. Cancer 2011, 117:4566-4572.
11. Haasbeek CJ, Palma D, Visser O, Lagerwaard FJ, Slotman BJ, Senan S Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands. Ann Oncol 2012, published online May 2. 10.1093/annonc/mds081.
12. Lagerwaard FJ, Verstegen NE, Haasbeek CJ, et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2012, 83:348-353.
13. Onishi H, Shirato H, Nagata Y, et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery?. Int J Radiat Oncol Biol Phys 2011, 81:1352-1358.
14. Palma D, Lagerwaard F, Rodrigues G, Haasbeek C, Senan S Curative treatment of stage I non-small-cell lung cancer in patients with severe COPD: stereotactic radiotherapy outcomes and systematic review. Int J Radiat Oncol Biol Phys 2012, 82:1149-1156.
15. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
16. TNM classification of malignant tumours 2002, 272. Union Internationale Contre le Cancer, Wiley-Liss, New York, NY. 6th edn.
17. Underberg RW, Lagerwaard FJ, Cuijpers JP, Slotman BJ, van Sornsen de Koste JR, Senan S Four-dimensional CT scans for treatment planning in stereotactic radiotherapy for stage I lung cancer. Int J Radiat Oncol Biol Phys 2004, 60:1283-1290.
18. Verbakel WF, Senan S, Cuijpers JP, Slotman BJ, Lagerwaard FJ Rapid delivery of stereotactic radiotherapy for peripheral lung tumors using volumetric intensity-modulated arcs. Radiother Oncol 2009, 93:122-124.
19. Hurkmans CW, Cuijpers JP, Lagerwaard FJ, et al. Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study. Radiat Oncol 2009, 4:1.
20. Lagerwaard FJ, Haasbeek CJ, Smit EF, Slotman BJ, Senan S Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008, 70:685-692.
21. Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995, 109:120-129.
22. Herder GJ, Kramer H, Hoekstra OS, et al. Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. J Clin Oncol 2006, 24:1800-1806.
23. van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002, 359:1388-1393.
24. Chi A, Liao Z, Nguyen NP, Xu J, Stea B, Komaki R Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications. Radiother Oncol 2010, 94:1-11.
25. Hung JJ, Hsu WH, Hsieh CC, et al. Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence. Thorax 2009, 64:192-196.
26. Rubins J, Unger M, Colice GL Follow-up and surveillance of the lung cancer patient following curative intent therapy: ACCP evidence-based clinical practice guideline (2nd edition). Chest 2007, 132(3 suppl):355S-367S.
27. Schmidt-Hansen M, Baldwin DR, Hasler E What is the most effective follow-up model for lung cancer patients? A systematic review. J Thorac Oncol 2012, published online April 4. 10.1097/JTO.0b013e31824afc55.
28. Huang K, Dahele M, Senan S, et al. Radiographic changes after lung stereotactic ablative radiotherapy (SABR)-can we distinguish recurrence from fibrosis? A systematic review of the literature. Radiother Oncol 2012, 102:335-342.
29. Gauger J, Patz EF, Coleman RE, Herndon JE Clinical stage I non-small cell lung cancer including FDG-PET imaging: sites and time to recurrence. J Thorac Oncol 2007, 2:499-505.
30. Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132(3 suppl):234S-242S.
31. Verstegen NE, Lagerwaard FJ, Haasbeek CJ, Slotman BJ, Senan S Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: comparison with a contemporaneous cohort with pathologically proven disease. Radiother Oncol 2011, 101:250-254.